share_log

Canaccord Genuity Upgrades Bioventus to Buy, Raises Price Target to $7

Benzinga ·  Dec 7, 2023 05:31

Canaccord Genuity analyst William Plovanic upgrades Bioventus (NASDAQ:BVS) from Hold to Buy and raises the price target from $3.66 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment